Peter Lynch fit · Growth at a reasonable price (GARP)
Is Arbutus Biopharma Corporation (ABUS) a Peter Lynch Stock?
Does not fit Lynch's GARP criteria - growth too low or price too high.
11/100
FNo encaja
1/6 criterios cumplidos
Los criterios de Peter Lynch, aplicados a ABUS
PEG ≤ 1.0
clave-
EPS CAGR ≥ 15%
clave-
Revenue CAGR ≥ 10%
6.4%
Net margin > 0
-237.9%
Cómo se valora ABUS en otras estrategias
Datos financieros en vivo
Cap. mercado
$859.29M
PER (TTM)
5.1x
ROIC (TTM)
56.72%
Margen bruto
99.98%
Otros análisis Peter Lynch
Preguntas frecuentes
What is ABUS's Peter Lynch fit score?
ABUS scores 11/100 on our Peter Lynch fit engine - grade F. Does not fit Lynch's GARP criteria - growth too low or price too high.
Does Peter Lynch actually own ABUS?
Our score is computed from financial fundamentals against Peter Lynch's published criteria. We don't claim that Peter Lynch personally owns or recommends ABUS.
How often is this score updated?
ABUS's Peter Lynch fit score is recomputed daily from the latest TTM financials. The page below shows when it was last refreshed.
Herramienta educativa, no es asesoramiento financiero. Las puntuaciones se calculan a partir de datos financieros públicos contra los criterios publicados de cada estrategia de inversión. No afirmamos que Peter Lynch posea o recomiende ABUS personalmente.